Teflaro Sanctioned for Bacterial Infections

powered by healthline

Average Ratings

Including pneumonia and methicillin-resistant staph

MONDAY, Nov. 1 (HealthDay News) -- The injected antibiotic Teflaro (ceftaroline fosamil) has been approved by the U.S. Food and Drug Administration to treat bacterial infections including community acquired bacterial pneumonia and methicillin-resistant Staphylococcus aureus (MRSA), the agency said in a news release.

MRSA, resistant to a host of common antibiotics, is typically acquired in hospitals and other health care settings.

Teflaro is among a class of antibiotics called cephalosporins, which treat infections by interfering with the bacterial cell wall.

In clinical testing, the most common side effects of Teflaro included diarrhea, nausea and rash. The drug shouldn't be used by people with a known history of allergy or sensitivity to cephalosporins, the FDA said.

More information

The FDA has more about this approval.


-- Scott Roberts
Copyright © 2010 HealthDay. All rights reserved.
Article from
Top of page
General Drug Tools
General Drug Tools view all tools
Tools for
Healthy Living
Tools for Healthy Living view all tools
Search Tools
Search Tools view all tools
Insurance Plan Tools
Insurance Plan Tools view all tools